|
|
||||||||


*
Department of Molecular Microbiology and Immunology, School of Hygiene and Public Health, and
Department of Pharmacology and Molecular Sciences, School of Medicine, Johns Hopkins University, Baltimore, MD 21205
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
One potential role has been demonstrated by Weissman et al. (9) who
induced CCR5-mediated chemotaxis with HIV envelope glycoprotein gp120.
Like fusion and infection, chemotaxis was strictly dependent upon
envelope binding to both the CD4 and CCR5 coreceptors. Similarly, Popik
et al. (10) have reported that activation of the MEK/ERK kinase
pathways could not be triggered by CXCR4 binding to gp120 in the
absence of CD4 binding. On the other hand, CD4-independent association
of T cell-tropic HIV-1 gp120 with CXCR4 occurs in T cell lines (11) and
neuronal cell lines and triggers Ca2+ flux and chemotaxis
(12, 13). Even Weissman et al. (9) found that cross-linking of surface
membrane CD4 was unnecessary for calcium flux in CD8+ T
cells as long as the soluble envelope had been preincubated with
soluble CD4. Moreover, Misse et al. (14) recently demonstrated that
removal of the conserved first
helical region of
HIV-1IIIB gp120 abrogated CD4 binding and infection, but
did not interfere with CXCR4 binding.
These findings suggest that mimicry of stromal-derived factor 1 (SDF-1)-induced CXCR4-mediated chemotaxis may not require CD4 binding at all. Therefore, we examined the ability of CXCR4-tropic HIV-1MN and macrophage- tropic HIV-1BaL virions or various denatured forms of CXCR4-tropic HIV-1IIIB gp120 to induce chemotaxis of human PBMCs. While the use of recombinant envelopes minimizes the possibility of cytokines confounding the interpretation of the results, we felt it was important to initially demonstrate the phenomena with infectious supernatants and purified virions to establish a case for biological relevance.
| Materials and Methods |
|---|
|
|
|---|
PBMCs were obtained by Ficoll-Hypaque (Sigma, St. Louis, MO)
centrifugation. The human CD4+ T cell line PM1 was obtained
from the National Institutes of Health AIDS Research and Reference
Reagent Program (Rockville, MD). Clinical use GMP grade, endotoxin-free
HIV-1IIIB rgp120, rcmgp120, and soluble CD4-Ig
were obtained from Genentech (San Francisco, CA). Gradient-purified
HIV-1MN and HIV-1BaL with an infectious titer
of 106.5 tissue culture ID50 were obtained from
Advanced Biotechnologies (Columbia, MD). CD4 blocking and nonblocking
Abs (National Institutes of Health AIDS Research and Reference Reagent
Program) and CXCR4 Abs were prepared in our laboratory (15).
RANTES, macrophage inflammatory protein 1ß (MIP-1ß), and SDF-1
were obtained from R&D Systems (Minneapolis, MN).
Virus infections
Human blood from normal HIV-negative adult volunteers was layered on a Ficoll-Hypaque gradient, centrifuged, and harvested for PBMCs. PBMCs were activated with 5 µg/ml PHA (Life Technologies, Gaithersburg, MD) for 2 days before infection. PHA-activated PBMCs (50 x 106) were incubated with 5 x 104 tissue culture ID50 HIV-1MN or HIV-1BaL in a total volume of 25 ml at 37°C in RPMI 1640 medium containing 10% FCS plus 2 U/ml IL-2 (Boehringer Mannheim, Indianapolis, IN). After 1 h, the cells were washed three times in PBS and cultured at 2 x 106/ml. HIV-1 p24 Ag in supernatants was assessed at day 7 postinfection by enzyme immunoassay (Organon Teknika, Durham, NC).
Chemotaxis assay
CD4+ and CD8+ cells were isolated by negative depletion using anti-CD4 and anti-CD8 magnetic beads (Dynal, Lake Success, NY) at saturating concentrations. The purity of T cell subsets was determined by flow cytometric analysis of cells immunostained with anti-CD4 and anti-CD8 mAbs (Coulter Immunology, Hialeah, FL) and detected with FITC-conjugated goat anti-mouse IgG (Jackson Immunoresearch Laboratories, Bar Harbor, ME). PHA plus IL-2-activated PBMCs or nonactivated CD4+ and CD8+ cells (20,000/well) incubated for 24 h in 2 U IL-2 were labeled with 5 µM calcein dye (Molecular Probes, Eugene, OR) and placed above filters with 5-µm pores overlying medium, chemokines, HIV-1 envelope protein, or HIV-1 virus in serial dilutions in 96-well microchemotaxis chambers (Neuroprobe, Gaithersburg, MD). After 1 h incubation at 37°C, labeled cells in the lower chamber were read in a fluorescence plate reader at 480EX/530EM. Because absolute numbers of migrating cells can vary substantially by donor and between experimental runs, results are normalized against migrating cells in control media (0.5% FCS, RPMI 1640) and expressed as the ratio of absolute cells or migration index (MI).
Calcium signaling
Cells were loaded with indo-1/acetoxymethylester (Molecular Probes) by incubation for 30 min at 37°C with 4 µM indo-1 per 106 cells in 20 mM HEPES, pH 7.4, containing 136 mM NaCl, 4.8 mM KCl, 1 mM CaCl2, and 5 mM glucose. After centrifugation, loaded cells were resuspended in the same buffer (106 cells/ml) and stimulated with the indicated chemokines or envelope protein at 37°C, and the fluorescence-related changes in intracellular-free calcium concentration ([Ca2+]) were recorded in a specifically designed fluorometer.
| Results |
|---|
|
|
|---|
A human CD4+ T cell line, PM1, permissive for both CXCR4- and CCR5-tropic HIV was infected with HIV-1MN and HIV-1BaL. On day 7, culture supernatants were collected and adjusted to equal virus p24 concentrations after measurement by enzyme immunoassay. The supernatants were then analyzed for their ability to induce chemotaxis of PHA/IL-2-activated PBMCs in a 96-well microchemotaxis chamber assay. Purified recombinant human RANTES was used as a positive control. The greatest migration was stimulated by HIV-1-infected cell culture supernatants, although uninfected PM1 supernatants were also moderately stimulatory: RANTES MI = 7.0; HIV-1MN MI = 6.5; HIV-1BaL MI = 8.0; uninfected supernatant MI = 1.3. Both HIV-1MN- and HIV-1BaL-infected cell supernatants showed chemotactic activity at a p24 concentration of 1 ng/ml, which exceeded maximal chemotaxis induced by RANTES (10 ng/ml).
To extend these findings to the virus grown in primary PBMCs, the
experiment was repeated using cell culture supernatants from infected
or uninfected activated PBMCs. Both HIV-1MN- and
HIV-1BaL-infected cell supernatants again showed
chemotactic activity at 1 ng/ml p24 comparable to the maximal
chemotactic activity of RANTES at 10 ng/ml (Fig. 1
A). A dose-response curve of
both HIV-1 supernatants showed a peak activity at 10 ng/ml p24
concentration, with a steady increase between 0.110 ng/ml and a sharp
fall in activity between 100 ng/ml and 1000 ng/ml. The uninfected
supernatant had no significant chemoattractant activity.
|
To rule out a requirement for virus-induced cytokines or infection
of migrating cells, we tested the chemoattractant activity of
gradient-purified UV-inactivated HIV-1IIIB. There was
potent chemotaxis to inactivated purified virus in a dose-dependent
manner, with maximal numbers of cells migrating at 10 ng/ml p24 (not
shown). To determine whether the viral envelope gp120 was chemotactic
in the absence of secreted cellular factors or additional viral
components, experiments were repeated using endotoxin-free purified
recombinant gp120 envelope protein from HIV-1IIIB
(Genentech), which showed significant chemoattractant activity, rising
sharply between 0.01 and 0.1 ng/ml, increasing to maximal at 10 ng/ml,
and decreasing between 100-1000 ng/ml. Fig. 1
B illustrates
the responses between 0.1 and 100 ng/ml. Similar CXCR4-mediated
dose-response migration was observed with heat-denatured gp120 (Fig. 1
B) and reduced carboxymethylated IIIB rgp120 (rcmgp120),
which does not bind CD4 (Fig. 2
A). To further rule out an
essential role for CD4 in gp120-mediated signaling through CXCR4, a mAb
(SIM4) that binds to the same epitope as Leu 3a and blocks HIV CD4
binding and infection was shown to have no inhibitory effect compared
with SIM7, a mAb which binds to the same epitope as Leu 3 and
does not compete for envelope binding to CD4 (Fig. 2
A). In
addition, gp120-induced chemotaxis of activated PBMC was not blocked by
soluble CD4-Ig fusion protein (Fig. 2
B).
|
. However,
as early as 6 h after culture without stimulation, resting PBMCs
expressed high levels of surface CXCR4 and responded dramatically to
these chemoattractants, albeit with somewhat less migration than seen
for activated cells at the 1 ng/ml concentration of rgp120 (Fig. 3
, but not by MIP-1ß, indicating a direct
interaction of gp120 with CXCR4 (Fig. 3
|
at 0.01100 ng/ml. Transient increases in cytosolic free
Ca2+ concentration were observed for both gp120 and
SDF1
, peaking at 20 s poststimulation and returning to resting
values within 5 min (data not shown). Thus, HIV-1IIIB gp120
can induce Ca2+ mobilization like the physiological
chemokine ligands, probably via the G protein-coupled pathway. Chemotaxis of CD4-CD8+ lymphocytes induced by the CXCR4-tropic envelope and virus
To assess the biological consequences of CD4 independent
gp120-CXCR4 interactions, PBMCs were immunomagnetically depleted of
CD4+ cells and the remaining cells (<2% CD4+,
85% CD8+) were used in chemotaxis assays with recombinant
envelopes and purified virions. Flow cytometry revealed comparable
expression by activated CD4 and CD8 cells of CXCR4 or CCR5. This was
further confirmed by similar dose-response curves of CD4 and CD8 cells
migrating toward SDF-1
or MIP-1ß. The <2% CD4+ cells
remaining in the CD4-depleted population cannot account for the
observed high migration indices, as MI > 6 represents migration
of more than half of the input cells. Furthermore, significant
migration of contaminating CD4+ cells should have been
observed equally in response to HIV-1BaL, and this was not
seen, as shown in Fig. 4
B. For
both HIV-1IIIB rgp120 and rcmgp120, chemotaxis of CD8 cells
was comparable to whole PBMCs (Fig. 4
A).
|
| Discussion |
|---|
|
|
|---|
Our results are consistent with previous observations on the ability of the IIIB envelope to stimulate calcium flux and chemotaxis in neuronal cells in a CXCR4-dependent, CD4-independent manner (13), but would seem to be at odds with the finding of Weissman et al. (9) that IIIB rgp120 and another CXCR4-tropic envelope failed to elicit Ca2+ fluxes even in CD4+ T cells. The differences may be due to our use of either unstimulated or PHA plus IL-2-stimulated cells rather than the anti-CD3 plus IL-2-activated cells used by these authors, as Riley et al. (21) have shown that different stimulation strategies can markedly influence CKR expression. The absence of signal transduction reported by Weissman and colleagues was not confirmed in our published studies demonstrating the ability of IIIB rgp120 to induce actin-mediated cocapping of CD4 and CXCR4 and cap-polarized pseudopod formation typical of chemotaxis (15).
Our experiments have shown that heat-denatured gp120 is capable of
signal transduction leading to chemotaxis. This suggests that the
amount of unfolding by our heat denaturation is sufficient to retain
the signal-transducing property of this protein. Our method of
denaturation is mild (56°C) and might still retain enough
conformation for CKR binding. Furthermore, the CXCR4 binding residues
are recessed in native trimeric gp120, and it is possible that mild
heating and denaturation actually increases their exposure and
availability for CKR binding. Along these lines, it has been reported
previously by Bandres et al. (11) that envelope deglycosylation
enhanced envelope binding to CKR. More recently, Misse et al. (14) have
demonstrated that a conserved
helical sequence can be removed from
the CXCR4-tropic virus envelope, thereby abrogating CD4 binding
and infectivity while preserving CXCR4 binding. Finally, SDF-1 and
synthetic ligands have relatively limited terminal regions that
effectively engage the CKR.
The advantage to HIV in attracting new infectable CD4+ potential host cells along a chemotactic gradient to loci of infection is obvious. It is less clear that any selective value is conferred on CXCR4-tropic strains by their ability to attract CD8 cells, and it may simply be an epiphenomenon of HIV envelope signaling through CXCR4. Flow analysis performed just before our chemotaxis studies clearly showed an absence of CD4 on the purified CD8+ cells used, as would be predicted by Flamand et al. (20) for cells not stimulated through the TCR. Therefore, expression of surface CD4 during the 1-h migration assay could not account for CXCR4-mediated binding. Also, any such surface expression of CD4 should have rendered the cells responsive to HIV-1BaL as well, and that was not the case. Of course, if the findings of Flamand et al. (20) are generally applicable in vivo, then attracting CD8 cells to lymph nodes where they could become activated and eventually express surface CD4 would provide additional targets for infection, especially late in disease when CD4+ lymphocytes might be rare.
Taking a broader view of viral evolution and pathogenesis, CD8 cells attracted to germinal centers where virus is tethered to follicular dendritic cells in immune complexes (22) may, through direct lysis or indirect release of cytokines, alter the microenvironment in ways that release and disseminate virions throughout the body (23, 24). Coupled with their more rapid rate of replication in T cells, widespread dissemination of CXCR4-tropic virions could represent a significant selective advantage. Alternatively, the ability to attract CD8 cells to sites of infection may be critical for the CXCR4-activated destruction of antiviral CD8 cells by TNF-mediated apoptosis in vivo. Such a mechanism requiring direct contact between macrophages and CD8 cells, has been described and is dramatically up-regulated by the CXCR-tropic envelope (25).
| Acknowledgments |
|---|
| Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. James E. K. Hildreth, Department of Pharmacology and Molecular Sciences, School of Medicine, Johns Hopkins University, Room 320A Physiology, 725 North Wolfe Street, Baltimore, MD 21205. E-mail address: ![]()
3 Abbreviations used in this paper: CKR, chemokine receptor; SDF-1, stromal-derived factor; MIP-1, macrophage inflammatory protein; ERK, extracellular signal-related kinase; MEK, mitogen-activated protein/ERK; MI, migration index. ![]()
Received for publication December 14, 1998. Accepted for publication February 26, 1999.
| References |
|---|
|
|
|---|
, MIP-1ß receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272:1955.[Abstract]
is mediated by the chemokine receptor CXCR4. Curr. Biol. 8:595.[Medline]
-helical conserved structure. J. Virol. 72:7280.This article has been cited by other articles:
![]() |
N. Thakkar, V. Pirrone, S. Passic, W. Zhu, V. Kholodovych, W. Welsh, R. F. Rando, M. E. Labib, B. Wigdahl, and F. C. Krebs Specific Interactions between the Viral Coreceptor CXCR4 and the Biguanide-Based Compound NB325 Mediate Inhibition of Human Immunodeficiency Virus Type 1 Infection Antimicrob. Agents Chemother., February 1, 2009; 53(2): 631 - 638. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Vasiliver-Shamis, M. Tuen, T. W. Wu, T. Starr, T. O. Cameron, R. Thomson, G. Kaur, J. Liu, M. L. Visciano, H. Li, et al. Human Immunodeficiency Virus Type 1 Envelope gp120 Induces a Stop Signal and Virological Synapse Formation in Noninfected CD4+ T Cells J. Virol., October 1, 2008; 82(19): 9445 - 9457. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Melar, D. E. Ott, and T. J. Hope Physiological Levels of Virion-Associated Human Immunodeficiency Virus Type 1 Envelope Induce Coreceptor-Dependent Calcium Flux J. Virol., February 15, 2007; 81(4): 1773 - 1785. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Badr, G. Borhis, D. Treton, C. Moog, O. Garraud, and Y. Richard HIV Type 1 Glycoprotein 120 Inhibits Human B Cell Chemotaxis to CXC Chemokine Ligand (CXCL) 12, CC Chemokine Ligand (CCL)20, and CCL21 J. Immunol., July 1, 2005; 175(1): 302 - 310. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Balabanian, J. Harriague, C. Decrion, B. Lagane, S. Shorte, F. Baleux, J.-L. Virelizier, F. Arenzana-Seisdedos, and L. A. Chakrabarti CXCR4-Tropic HIV-1 Envelope Glycoprotein Functions as a Viral Chemokine in Unstimulated Primary CD4+ T Lymphocytes J. Immunol., December 15, 2004; 173(12): 7150 - 7160. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Brainard, W. G. Tharp, E. Granado, N. Miller, A. K. Trocha, X.-H. Ren, B. Conrad, E. F. Terwilliger, R. Wyatt, B. D. Walker, et al. Migration of Antigen-Specific T Cells Away from CXCR4-Binding Human Immunodeficiency Virus Type 1 gp120 J. Virol., May 15, 2004; 78(10): 5184 - 5193. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Masci, M. Galgani, S. Cassano, S. De Simone, A. Gallo, V. De Rosa, S. Zappacosta, and L. Racioppi HIV-1 gp120 induces anergy in naive T lymphocytes through CD4-independent protein kinase-A-mediated signaling J. Leukoc. Biol., December 1, 2003; 74(6): 1117 - 1124. [Abstract] [Full Text] |
||||
![]() |
G. Lin, F. Baribaud, J. Romano, R. W. Doms, and J. A. Hoxie Identification of gp120 Binding Sites on CXCR4 by Using CD4-Independent Human Immunodeficiency Virus Type 2 Env Proteins J. Virol., December 20, 2002; 77(2): 931 - 942. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Hale-Donze, T. Greenwell-Wild, D. Mizel, T. M. Doherty, D. Chatterjee, J. M. Orenstein, and S. M. Wahl Mycobacterium avium Complex Promotes Recruitment of Monocyte Hosts for HIV-1 and Bacteria J. Immunol., October 1, 2002; 169(7): 3854 - 3862. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. G. Kitchen, S. LaForge, V. P. Patel, C. M. Kitchen, M. C. Miceli, and J. A. Zack Activation of CD8 T cells induces expression of CD4, which functions as a chemotactic receptor Blood, January 1, 2002; 99(1): 207 - 212. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. R. Lane, R. M. Strieter, M. J. Coffey, and D. M. Markovitz Human Immunodeficiency Virus Type 1 (HIV-1)-Induced GRO-{alpha} Production Stimulates HIV-1 Replication in Macrophages and T Lymphocytes J. Virol., July 1, 2001; 75(13): 5812 - 5822. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. J. Hewson, J. J. Logie, P. Simmonds, and S. E. M. Howie A CCR5-Dependent Novel Mechanism for Type 1 HIV gp120 Induced Loss of Macrophage Cell Surface CD4 J. Immunol., April 15, 2001; 166(8): 4835 - 4842. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Hladik, S. Bender, R. E. Akridge, Y. Hu, C. Galloway, D. Francis, and M. J. McElrath Recombinant HIV-1 Glycoprotein 120 Induces Distinct Types of Delayed Hypersensitivity in Persons With or Without Pre-Existing Immunologic Memory J. Immunol., March 1, 2001; 166(5): 3580 - 3588. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. T. Scadden, H. Shen, and T. Cheng Hematopoietic Stem Cells in HIV Disease J Natl Cancer Inst Monographs, December 1, 2000; 2000(28): 24 - 29. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-L. Lin, A. K. Sewell, G. F. Gao, K. T. Whelan, R. E. Phillips, and J. M. Austyn Macrophage-Tropic HIV Induces and Exploits Dendritic Cell Chemotaxis J. Exp. Med., August 21, 2000; 192(4): 587 - 594. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Iyengar, D. H. Schwartz, J. E. Clements, and J. E. K. Hildreth CD4-Independent, CCR5-Dependent Simian Immunodeficiency Virus Infection and Chemotaxis of Human Cells J. Virol., August 1, 2000; 74(15): 6720 - 6724. [Abstract] [Full Text] |
||||
![]() |
K. Salzwedel, E. D. Smith, B. Dey, and E. A. Berger Sequential CD4-Coreceptor Interactions in Human Immunodeficiency Virus Type 1 Env Function: Soluble CD4 Activates Env for Coreceptor-Dependent Fusion and Reveals Blocking Activities of Antibodies against Cryptic Conserved Epitopes on gp120 J. Virol., January 1, 2000; 74(1): 326 - 333. [Abstract] [Full Text] |
||||
![]() |
J. Zheng, A. Ghorpade, D. Niemann, R. L. Cotter, M. R. Thylin, L. Epstein, J. M. Swartz, R. B. Shepard, X. Liu, A. Nukuna, et al. Lymphotropic Virions Affect Chemokine Receptor-Mediated Neural Signaling and Apoptosis: Implications for Human Immunodeficiency Virus Type 1-Associated Dementia J. Virol., October 1, 1999; 73(10): 8256 - 8267. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Wang and J. J. Oppenheim Interference with the Signaling Capacity of Cc Chemokine Receptor 5 Can Compromise Its Role as an HIV-1 Entry Coreceptor in Primary T Lymphocytes J. Exp. Med., September 6, 1999; 190(5): 591 - 596. [Full Text] [PDF] |
||||
![]() |
A. Brelot, N. Heveker, M. Montes, and M. Alizon Identification of Residues of CXCR4 Critical for Human Immunodeficiency Virus Coreceptor and Chemokine Receptor Activities J. Biol. Chem., July 28, 2000; 275(31): 23736 - 23744. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |